Clinical trials: Neoplasms by Histologic Type
Leukemia
Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia
RATIONALE: Immunotoxins, such as anti-CD19 and anti-CD22, can find cancer cells that express CD19 and CD22 and kill them without harming normal cells. This may be an effective treatment for B-cell acute lymphoblastic leukemia.
- Trial name
- NCT00450944
- Testing
- deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Albert Einstein College of Medicine
Liposarcoma, Recurrent Liposarcoma
BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma
This study is testing two different doses of BTX-A51 to determine if it is safe and tolerable in participants with liposarcoma with MDM2 amplification, myxoid liposarcoma, and CIC-rearranged sarcoma.
- Conditions
- Liposarcoma, Recurrent Liposarcoma, Metastatic Liposarcoma, Unresectable Liposarcoma
- Trial name
- NCT06414434
- Testing
- BTX-A51
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Michael Wagner, MD
Leukemia
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- AML-19 (NCT00091234)
- Testing
- gemtuzumab ozogamicin
- Where
- 45 sites in Belgium, Italy and 1 more
- Volunteers
- 279 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pancreatic Ductal Adenocarcinoma, Sarcoma
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
The purpose of this Phase 1b study is to assess the safety and maximum tolerated dose (MTD) of Decitabine in combination with Gemcitabine among previously treated patients diagnosed with advanced pancreatic adenocarcinoma or…
- Trial name
- NCT02959164
- Testing
- Decitabine, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mohammed Milhem
Lymphoma
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
This study will evaluate the efficacy and safety of MabThera plus high dose methotrexate plus high dose cytarabine in patients with central nervous system non-Hodgkin's lymphoma.
- Trial name
- NCT00517699
- Testing
- rituximab [MabThera/Rituxan], Methotrexate, Cytarabine
- Where
- 2 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Gastrointestinal Cancer
Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers
Sildenafil increases the therapeutic effect of doxorubicin used as treatment for cancers of solid tumors through both an increase in anti-tumor effects and protection from cardiac toxicity.
- Conditions
- Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Sarcoma
- Trial name
- NCT01375699
- Testing
- Doxorubicin, Sildenafil
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Liver Cancer
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer
RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01005199
- Testing
- everolimus, sorafenib tosylate
- Where
- 15 sites in Austria, Hungary and 1 more
- Volunteers
- 106 people
- Sponsor
- Swiss Cancer Institute
Acute Myeloid Leukemia, Adult
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of Acute Myeloid Leukemia (AML) patients in the first line with intensive chemotherapy based…
- Trial name
- NCT05127798
- Testing
- Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.
- Where
- 2 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Fallopian Tube Cancer, Peritoneal Cavity Cancer
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and pegylated liposomal doxorubicin hydrochloride (PLD) work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT01281514
- Testing
- everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1a is an open-label, multi-dose, single-arm, dose-escalation study to define the toxicity profile, pharmacokinetics, and antitumor activity of SGN-33 in patients with myelodysplastic syndrome (MDS), acute myelogenous…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00283114
- Testing
- lintuzumab
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Seagen Inc.
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
Melanoma
Neoadjuvant T-VEC in High Risk Early Melanoma
Despite the recent notable advances in the treatment of advanced melanoma with application of growing immunotherapies, patterns of response and factors resulting in treatment failure are poorly understood.
- Trial name
- NCT04427306
- Testing
- T-Vec
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Ulcerative Colitis, Colorectal Cancer
Subjective Near-infrared Fluorescence Guidance in Perfusion Assessment of Ileal Pouch Formation and Ileal-pouch-anal Anastomosis
In this prospective, non-randomized cohort study, real-time intraoperative visualization using near-infrared-fluorescence by indocyanine green injection (ICG-NIRF) is performed at three time points during ileal pouch…
- Conditions
- Ulcerative Colitis, Colorectal Cancer, Crohn Disease, Familial Adenomatous Polyposis
- Trial name
- NCT04695184
- Testing
- ICG-NIRF Imaging
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Stage IV Nasopharyngeal Carcinoma
Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma
This is an open-label, uncontrolled, multicenter phase II clinical trial. The purpose of this study is to evaluate acute toxicity and efficacy of cisplatin and 5-Fu combined with nimotuzumab in patients with untreated metastatic…
- Trial name
- NCT01616849
- Testing
- cisplatin and 5-Fu combined with nimotuzumab
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Leukemia
Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients
The goal of this clinical research study is to learn if urelumab given in combination with rituximab can help to control CLL or SLL. The safety of the drug combination will also be studied.
- Trial name
- NCT02420938
- Testing
- Rituximab, Urelumab
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Lymphocytic Leukemia, Chronic
- Trial name
- NCT00241358
- Testing
- AMD3100, Stem Cell Transplant
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Washington University School of Medicine
Neuroendocrine Carcinoma
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
Cisplatin and Etoposide is the standard of care in NEC originating from the gastro-intestinal tract and lung, based on retrospective studies.
- Trial name
- NCT02687958
- Testing
- Everolimus
- Where
- 5 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Acute Lymphoblastic Leukemia
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia
This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous chimeric antigen receptor (CAR) T cells targeting both CD19 and CD22, manufactured with T-Charge(TM) process.
- Trial name
- NCT05168748
- Testing
- IMJ995 single agent
- Sponsor
- Novartis Pharmaceuticals
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma
The purpose of this study is to find out the effects of a drug called LBH589 when given to people with recurrent or refractory Hodgkin or Non-Hodgkin's lymphoma. The safety of this drug will also be studied.
- Trial name
- NCT01032148
- Testing
- LBH589
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
The primary objective of this study is to determine the safety and tolerability of utilizing the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of advanced, previously treated myelodysplastic…
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Anemia, Refractory, With Excess of Blasts
- Trial name
- NCT03175978
- Testing
- IGF/MTX
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- IGF Oncology, LLC